Exhibit 10.3

[***] Certain information in this document has been  {E1 excluded}  pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely  {E2 cause}  competitive {E51 harm} to the registrant if publicly  {E3 disclosed}  . Execution Copy

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

{E5 DATED}  AS OF FEBRUARY 4,  2020

BY AND BETWEEN

XENCOR, INC. AND

AIMMUNE THERAPEUTICS, INC. Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

TABLE OF CONTENTS Page ARTICLE 1 Definitions 1

ARTICLE 2 Licenses 13

ARTICLE 3 Development 16

ARTICLE 4 Regulatory 17

ARTICLE 5 Commercialization 19

ARTICLE 6 Supply 20

ARTICLE 7 Payments 21

ARTICLE 8 Payment; Records; Audits 24

ARTICLE 9 Intellectual Property Matters 26

ARTICLE 10 Representations, Warranties and Covenants; Compliance 31

ARTICLE 11 Indemnification 34

ARTICLE 12 Confidentiality 36

ARTICLE 13  Term  and Termination 40

ARTICLE 14 Effects of Expiration Or Termination 40

ARTICLE 15 Miscellaneous 43

Schedule 1.10 Antibody 50

Schedule 1.79 Xencor General Patents 51

Schedule 1.81 Xencor Product Specific Patents 52

Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data 53

Schedule 6.1 Initial Product Supply 54

Schedule 10.2.6 Exceptions 55

Schedule 12.2 Initial Press Release 56

Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

This License, Development and Commercialization Agreement (this "Agreement"),  {E5 dated}  as of  February 4, 2020  (the "Effective  Date  "), is  {E6 made}  by and between Xencor, Inc. ("Xencor"), and Aimmune Therapeutics, Inc. ("Aimmune"). Xencor and Aimmune are sometimes  {E7 referred}  to herein individually as a "Party" and collectively as the "Parties". RECITALS

WHEREAS, Xencor has  {E8 developed}  the Antibody (as  {E9 defined}  below);

WHEREAS, Aimmune is interested in further  {E10 developing}  and  {E11 commercializing}  the Antibody; and

WHEREAS, Xencor  {E12 wishes}  to  {E13 grant}  a license to Aimmune under certain intellectual property rights  {E14 related}  to the Antibody to  {E15 develop}  ,  {E16 manufacture}  and  {E17 commercialize}  the Product (as  {E18 defined}  below), and Aimmune  {E19 wishes}  to  {E20 take}  such license, in each case in accordance with the terms and conditions set forth below. NO W THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions  {E21 contained}  in this Agreement, and for other good and valuable consideration, {E52 receipt} of which is hereby  {E22 acknowledged}  , the Parties  {E23 agree}  as  follows  :

ARTICLE 1 DEFINITIONS

As  {E24 used}  in this Agreement, the  following  initially  {E25 capitalized}  terms shall have the meanings set forth in this ARTICLE 1 or as otherwise  {E26 defined}  elsewhere in this Agreement:

1.1 "Active Ingredient" means any substance (whether chemical or biologic) or mixture of substances intended to be used in the {E53 manufacture} of a drug (medicinal) product that, when used in the {E54 production} of such drug, becomes a therapeutically active ingredient of the drug product, and which such substance or mixture of substances is intended to furnish pharmacological {E55 activity} or other direct {E56 effect} in the {E57 diagnosis}, {E58 cure}, {E59 mitigation}, {E60 treatment} or {E61 prevention} of disease or to affect the structure or function of the body. 1.2 "Affiliate" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with such person; provided, that, for purposes of this definition, "control" (including, with correlative meanings, the terms "controlled by" and "under common control with"), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the direction of the {E62 management} and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, "person" means mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a "person" as defined in Section 13(d)(3) of the Securities Exchange Act of  1934 , as amended, together with the rules and regulations promulgated thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government. 1

Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

1.3 "Aimmune Agreement Entities" means Aimmune's Affiliates and Sublicensees (excluding distributors). 1.4 "Aimmune Common Stock" means Aimmune's common stock, par value $0.0001 per share. 1.5 "Aimmune Field" means the field of [***]. 1.6 "Aimmune Invention" means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates. 1.7 "Aimmune Know-How" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as of the Effective  Date  or at any time during the  Term  that is necessary or reasonably useful in connection with the {E67 Development}, {E68 Manufacture}, {E115 Commercialization} or other {E70 use} of the Antibody or Product. 1.8 "Aimmune Patent" means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective  Date  or comes under the Control of Aimmune (or its Affiliates) during the  Term  (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and (b) that would be infringed by the {E67 Development}, {E68 Manufacture}, {E115 Commercialization} or {E70 use} of the Antibody or Product or that claims or Covers Aimmune Know-How, or (ii) is an Aimmune Collaboration Patent. 1.9 "Aimmune Technology" means Aimmune Know-How and Aimmune Patents. 1.10 "Antibody" means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10. 1.11 "Anti-Corruption Laws" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act  2010 , as amended, as well as Applicable Law related to the {E71 prevention} of {E72 fraud}, {E73 racketeering}, {E74 money laundering} or {E75 terrorism}. 1.12 "Applicable Law" means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any {E76 order}, {E79 writ}, {E77 judgment}, {E78 injunction}, {E80 decree}, {E81 stipulation}, {E82 ruling}, {E83 determination} or {E84 award} entered by or with any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be  {E27 deemed}  to  {E28 include}  all then-  current  amendments  thereto  or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, {E85 order}, {E86 writ}, {E87 judgment}, {E88 injunction}, {E89 decree}, {E90 stipulation}, {E91 ruling}, or {E92 determination} thereto. 2

Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

1.13 "Baseline Quarter Net Sales" means, on a country-by-country and Product-by-Product basis, the average cumulative Net Sales of such Product in such country during the [***] Calendar Quarters that [***]precede the Calendar Quarter during which a Generic Product with respect to such Product is first commercially sold in such country. For example, if a Generic Product with respect to a  {E29 given}  Product is commercially  {E30 sold}  in the U.S. for the first time on [***], then the Baseline Quarter Net Sales with respect to such Product and U.S. are the cumulative Net Sales of such Product in the U.S. during the [***] Calendar Quarters of [***]  {E31 divided}  by [***]. 1.14 "Business Day" means  a day  other than a  Saturday ,  Sunday , or bank or other public holiday in California. 1.15 "Calendar Quarter" means each three (3)  month  period commencing  January 1 ,  April 1 ,  July 1  or  October 1  of any  year  ; provided, however, that (a) the first Calendar Quarter of the  Term  shall extend from the Effective  Date  to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the  Term  shall {E48 end} upon the {E96 expiration} or {E95 termination} of this Agreement. 1.16 "Calendar Year" means the period beginning on  the 1st of January  and ending on  the 31st of December of the same year ; provided, however, that (a) the first Calendar Year of the  Term  shall {E49 commence} on the Effective  Date  and {E50 end} on  December 31 of the same year  and (b) the last Calendar Year of the  Term  shall commence on  January 1  of the Calendar Year in which this Agreement terminates or expires and end on the date of {E95 termination} or {E96 expiration} of this Agreement. 1.17 "Clinical {E97 Trial}" means a clinical {E97 trial}, including any a Phase I Clinical {E99 Trial}, Phase II Clinical {E100 Trial}, Phase III Clinical {E101 Trial}, or Phase IV Clinical {E102 Trial}, as the case may be, and as any such {E97 trial} is defined by an applicable Regulatory Authority. 1.18 " Co  -pay {E105 Program}" means a {E105 program} to support patient access to a Product whereby the Product manufacturer makes {E106 payments} to a Third Party equal to all or part of the difference between the price of Product prescribed to a patient and the amount such patient pays for such Product through such patient's insurance plan. 1.19 "Combination Product" means any Product containing an Active Ingredient that is not an Antibody. Such Combination Product shall be either (a)  {E32 priced}  and  {E33 sold}  in a single package  {E34 containing}  such multiple products or (b)  {E35 packaged}  separately but  {E36 sold}  together for a single price. 1.20 "Commercialize" means, with respect to the Product, to promote, market, distribute, sell (and offer for sale or contract to sell), import, export, or otherwise commercially exploit or provide product {E107 support} for the Product and to conduct {E108 activities}, other than {E67 Development} or {E68 Manufacturing}, in {E111 preparation} for conducting the foregoing {E112 activities}, including {E113 activities} to produce commercialization support data and to secure and maintain market access and {E114 reimbursement}. " {E115 Commercializing}  " and "{E115 Commercialization}" shall have correlative meanings. For the avoidance of doubt, Commercialization  does  not  {E37 include}  Development and Manufacturing. 3

Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

1.21 "Commercially Reasonable {E126 Efforts}" means, with respect to the {E126 efforts} to be expended by a Party with respect to any objective (e.g., Development {E67 Activities} and {E115 Commercialization} hereunder), the level of {E126 efforts} consistent with the {E122 efforts} and resources [***] of similar market potential, at a similar stage in {E123 development} or product lifecycle, taking into account the stage of {E124 development} or product lifecycle of other of [***] product candidates, safety and efficacy, product profile, cost of goods, the competitiveness of the marketplace, such company's patent position with respect to such product (including such company's ability to obtain or enforce, or have obtained or enforced, such patent rights), the Third Party patent landscape relevant to the product, the regulatory structure involved, the likelihood of regulatory {E125 approval}, the likelihood and extent of anticipated or actual profitability of the applicable product, and other technical, legal, scientific and medical considerations. Without  {E38 limiting}  the foregoing, Commercially Reasonable {E126 Efforts}  {E39 requires}  , with respect to such obligations, that a Party: (i) promptly  {E40 assign}  responsibility for such obligation to specific employee(s) who are  {E41 held}  accountable for {E128 progress} and  {E42 monitor}  such {E128 progress} on an on- {E43 going}  basis, (ii) set objectives for  {E44 carrying}  out such obligations, and (iii)  {E45 allocate}  resources  {E46 designed}  to  {E47 advance}  {E128 progress} with respect to such objectives. 1.22 "Control" or " Controlled  by" means, with respect to any Know-How, Invention, Patent, technology, copyright, trademark or other intellectual property right, possession by a Party or its Affiliates (whether by ownership, license grant or other means) of the legal right to grant the right to access or use, or to grant a license or a sublicense to, such Know-How, Invention, Patent, technology, copyright, trademark or other intellectual property right as provided for herein without violating the proprietary rights of any Third Party or any terms of any agreement or other arrangement between such Party (or any of its Affiliates) and any Third Party. 1.23 "Cover" or " Covering  " means, with respect to a particular subject matter at issue and a relevant Patent, that the {E130 manufacture}, {E131 use}, {E132 sale}, {E133 offer} for {E134 sale} or {E135 importation} of such subject matter would, but for the existence of this Agreement, infringe one or more {E136 claims} in such Patents (or in the case of a Patent application, would infringe if such application were to issue). 1.24 "Designated Officer" means, with respect to Xencor, the Chief Executive Officer of Xencor (or its designee), and, with respect to Aimmune, the Chief Executive Officer of Aimmune (or its designee). 1.25 "Develop" means to research, develop, analyze, test and conduct preclinical {E137 trials}, Clinical {E138 Trials} (including, for the avoidance of doubt, Phase IV Clinical {E139 Trials} and any preclinical/clinical/CMC commitments following Regulatory {E140 Approval}) and all other regulatory {E141 trials}, for the Product, as well as any and all {E142 activities} pertaining to manufacturing {E143 development}, formulation {E144 development}, medical {E145 affairs} and lifecycle {E146 management}, including new {E188 indications}, new {E189 formulations} and all other {E147 activities}, including regulatory {E148 activities}, related to securing and maintaining Regulatory {E149 Approval} for the Product, or otherwise characterizing or understanding the properties and {E150 uses} of the Antibody or the Product. " {E152 Developing}  " and "{E152 Development}" shall have correlative meanings. 4

Source: AIMMUNE THERAPEUTICS, INC., 8-K,  2/5/2020

1.26 "Development {E154 Activities}" means those Development {E154 activities} undertaken by or on behalf of Aimmune with respect to the Product. 1.27 "Dollar" or "$" means the legal tender of the United States of America. 1.28 "E.U. Major Countries" means the United Kingdom, France, Germany, Italy, and Spain. 1.29 "FDA" means the United States Food and Drug Administration and any successor Regulatory Authority having substantially the same function. 1.30 "FD&C Act" means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder. 1.31 "First Commercial {E160 Sale}" means, with respect to a Product in any country, the first {E160 shipment} of such Product to a Third Party in such country for end {E157 use} or {E158 consumption} of such Product in such country after Regulatory {E159 Approval} of such Product in such country or, if earlier, the invoicing of a Third Party for such {E160 shipment}. 1.32 "Force Majeure" means any circumstances whatsoever which are not within the reasonable control of the Party affected thereby, potentially including an {E161 act} of God, {E162 war}, {E163 act} of terrorism, {E164 insurrection}, {E165 riot}, {E166 strike} or {E167 labor dispute}, {E168 shortage} of materials, {E169 fire}, {E170 explosion}, {E171 flood}, {E172 earthquake}, government {E173 requisition} or {E174 allocation}, {E175 breakdown} of or {E176 damage} to plant, equipment or facilities, {E177 interruption} or {E178 delay} in {E179 transportation}, fuel supplies or electrical power, {E180 embargo}, {E181 boycott}, {E182 order} or {E183 act} of civil or military authority. 1.33 "Generic Product" means, with respect to a Product and on a country-by-country basis, a product that (a) is marketed for {E184 sale} in such country [***], (b) contains or comprises an antibody with the [***], (c) is approved [***], and (d) such product, as and to the extent required, is approved through an abbreviated process based in reliance, at least in part, on the safety and efficacy data generated for the prior Regulatory {E159 Approval} of such Product by Aimmune or an Aimmune Agreement Entity in such country (similar, with respect to the United States, to an Abbreviated New Drug Applications under Section 505(j) of the FD&C Act (21 USC 355(j))) or is approved as a "Biosimilar Biologic Product" under Title VII, Subtitle A Biologics Price Competition and Innovation Act of  2009 , Section 42 U.S.C. 262, Section 351 of the PHSA, or, outside the United States, in accordance with European Directive  2001 /83/EC on the Community Code for medicinal products (Article 10(4) and Section 4, Part II of Annex I) and European Regulation EEC/ 2309 /93 establishing the community procedures for the {E185 authorization} and {E186 evaluation} of medicinal products, each as amended, and together with all associated guidance, and any counterparts thereof or equivalent process inside or outside of the United States or EU to the foregoing.



#COLOR:E5=hsl(0, 100%, 80%)
#COLOR:E67=hsl(25, 100%, 80%)
#COLOR:E68=hsl(50, 100%, 80%)
#COLOR:E115=hsl(225, 100%, 80%)
#COLOR:E70=hsl(100, 100%, 80%)
#COLOR:E96=hsl(150, 100%, 80%)
#COLOR:E95=hsl(125, 100%, 80%)
#COLOR:E97=hsl(175, 100%, 80%)
#COLOR:E105=hsl(200, 100%, 80%)
#COLOR:E126=hsl(250, 100%, 80%)
#COLOR:E128=hsl(275, 100%, 80%)
#COLOR:E152=hsl(300, 100%, 80%)
#COLOR:E154=hsl(325, 100%, 80%)
#COLOR:E160=hsl(350, 100%, 80%)
#COLOR:E159=hsl(75, 100%, 80%)

#TOKENIZATION-TYPE:1

